Keptrix Mechanism of Action

Pharmacology: Pharmacodynamics: Ceftriaxone (KEPTRIX) is a third-generation cephalosporin. It inhibits mucopeptide synthesis in the bacterial cell wall, making it defective and osmotically unstable. Ceftriaxone (KEPTRIX) is highly stable to most beta-lactamases and therefore, it is active against a wider spectrum of gram-negative bacteria and most Enterobacteriaceae. It is not active against gram-positive cocci as compared to the first and second generation cephalosporins. In vitro the activities of Ceftriaxone (KEPTRIX) and Aminoglycosides are synergistic against certain susceptible and resistant strains of P. aeruginosa, S. marcescens and other Enterobacteriaceae, including Enterobacter cloacae, E. coli, K. pneumoniae and P. mirabilis.
Pharmacokinetics: Ceftriaxone (KEPTRIX) is widely distributed in body tissues and fluids. It crosses both inflamed and non-inflamed meninges, generally achieving therapeutic concentrations in the CSF. It crosses the placenta and low concentrations have been detected in breast milk.
High concentrations are achieved in bile.
About 40 to 65% of a dose of Ceftriaxone (KEPTRIX) is excreted unchanged in the urine, principally by glomerular filtration; the remainder is excreted in the bile and is ultimately found in the feces as unchanged drug and microbiologically inactive compounds.